|
Trio of biomarkers may help identify early stage kidney cancer. |
 |
 |
|
EurekAlert: Next, the researchers tested the ability of the immunoassay to distinguish plasma samples from healthy controls and patients with kidney cancer using the same 189 plasma samples already tested. The results indicated that the three-marker assay was highly accurate. When it correctly identified 90 percent of the samples from healthy controls, it also correctly identified 94.4 percent of the samples from patients with kidney cancer. To validate the accuracy of the test, the researchers blind tested an additional 100 plasma samples from 73 healthy controls and 27 patients with kidney cancer. In this analysis, 67 of the samples from the 73 healthy controls and all of the samples from patients with kidney cancer were classified correctly.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
